期刊文献+

多塞平3mg治疗单纯末段失眠临床观察 被引量:1

To Observe Effects of Low-dose Doxepin 3 mg for Terminal Insomnia
下载PDF
导出
摘要 目的:观察对比多塞平(3 mg)和艾司唑仑治疗末段失眠效果。方法:60例末段失眠患者随机分为治疗组和对照组。治疗组:多塞平片3 mg/次,每日或隔日用药。对照组:艾司唑仑片1~2 mg/次,服药方法同前。2组患者治疗观察4周。结果:2组睡眠因子评分在治疗后较治疗前有显著减少(P<0.05);2组间主要睡眠因子评分对比没有显著性差异(P>0.05)。结论:小剂量多塞平治疗末段失眠有效。 Objective: To observe effects of low-dose doxepin (3 mg ) for the treatment terminal insomnia. Methods : 60 cases of patients withl terminal insomnia were randomly divided into two groups. Treatment group 30 cases, doxepin 3 mg/times oral, once a day or other day. Control group 30 cases, the estazolam tablet 1 mg/times, medication method ibid. Two groups of the patients were observed for 4 weeks. Results: Sleep factors score were signifi- cantly decreased (P 〈 0. 05) after treatment of two groups than before, There was no significant difference between the two groups of the main sleep factors score comparison ( P 〉 0.05 ) . Conclusion: low-dose doxepin ( 3 mg) is effective in the treatment of the terminal insomnia.
作者 滑宏巨 孙维红 张华 余建强 李玉香 于振清 王志红 Hua Hongju Sun Weihong Zhang Hua Yu Jianqiang Li Yuxiang Yu Zhenqing Wang Zhihong(Ningxia Academy of TCM, Yinchuan, 750021 Affiliated Hospital of Ningxia Medical University, Yinchuan, 750004 Ningxia Medical University, Yinchuan, 750004 Ningxia Tongxin County Hospital of TCM, Tongxin, 751300)
出处 《世界睡眠医学杂志》 2017年第3期157-160,共4页 World Journal of Sleep Medicine
基金 宁夏回族自治区科技支撑计划项目宁科计字2013(20)号
关键词 失眠 多塞平 艾司唑仑 阿森斯失眠量表 Insomnia Doxepin Estazolam AIS
  • 相关文献

参考文献3

二级参考文献21

  • 1阳红,查红,裴柯平.国际疾病分类(ICD-10)的应用[J].西南国防医药,2004,14(1):89-90. 被引量:19
  • 2宿长军,刘煜,李柱一,林宏,李宏增,苗建亭.黛力新与多塞平联合治疗原发性失眠[J].第四军医大学学报,2005,26(21):2010-2012. 被引量:17
  • 3王桂清,赵克虎.扩血管药联合多虑平治疗中老年人慢性失眠52例[J].实用医药杂志,2006,23(7):863-863. 被引量:3
  • 4Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin lmg, 3mg, and 6mg in adults with primary insomnia[ J]. Sleep,2007,30( 11 ) :1555-1561.
  • 5Roth T, Durrence H, Gotfried M, et al. Efficacy and safety of doxepin 1 and 3mg in a 3-month trial of elderly adults with chronic insomnia[J].Sleep, 2008,31 (9) :230.
  • 6Krystal AD, Durrence HH, Scharf M. et al. Efficacy and safety of doxepin 1 and 3rag in a 12-week sleep laboratory and outpatient tri- al of elderly subjeects with chronic primary insomnia [ J ]. Sleep, 2010,33 ( 11 ) : 1553-1561.
  • 7Krystal AD, Lankford A, Durrence HH, et al. Efficacy and Safety of Doxepin 3 and 6 mg in a 35-day Sleep Laboratory Trial in Adults with Chronic Primary Insomnia [J]. Sleep , 2011,34 ( 10 ) : 1433- 1442.
  • 8Jigar K, Anaada KK, Jaykumar JS, et al. Therapetie rationale for low dose doxepin in insomnia patients [ J ]. Asian Pacific journal of Tropical Disease, 2013,3(6) :331-336.
  • 9Buysse D J, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Re- search [ J ]. Psychiatric Research, 1989,28 ( 2 ) : 193.
  • 10Stahl SM. selective histamine HI antagonism: novel hypnoticand Pharmacologic actions challenge classical notions of antihistamines [ J]. CNS Spectrums. 2008,13 (12) : 1027-1038.

共引文献27

同被引文献7

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部